Medicine and Health Sciences Commons^™

Is Methylphenidate Effective In Reducing Apathy Among Alzheimer’S Disease Patients?, Jeremy Rinaldi

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE The objective of this selective EBM review is to determine whether or not “Is methylphenidate effective in reducing apathy among Alzheimer’s disease patients?”

STUDY DESIGN Systematic review of two randomized controlled trials published in 2008 and 2013 and one open label study published in 2010.

DATA SOURCES Two randomized controlled trials and one open label study were obtained using PubMed and Medline.

OUTCOMES MEASURED The focus of this review is to determine the efficacy of methylphenidate in decreasing symptoms of apathy in Alzheimer’s disease patients. The efficacy of methylphenidate was assessed in all three studies by using the Apathy …

Role Of Microbes In The Development Of Alzheimer's Disease: State Of The Art - An International Symposium Presented At The 2017 Iagg Congress In San Francisco., Tamàs Fülöp, Ruth F Itzhaki, Brian J. Balin Phd, Judith Miklossy, Annelise E Barron

PCOM Scholarly Papers

This article reviews research results and ideas presented at a special symposium at the International Association of Gerontology and Geriatrics (IAGG) Congress held in July 2017 in San Francisco. Five researchers presented their results related to infection and Alzheimer's disease (AD). Prof. Itzhaki presented her work on the role of viruses, specifically HSV-1, in the pathogenesis of AD. She maintains that although it is true that most people harbor HSV-1 infection, either latent or active, nonetheless aspects of herpes infection can play a role in the pathogenesis of AD, based on extensive experimental evidence from AD brains and infected cell …

Is Memantine A Safe And Effective Treatment For Alzheimer’S Disease In Patients Over The Age Of 50?, Stephanie Hoarau

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE The objective of this selective EBM review is to determine whether or not memantine is a safe and effective treatment for Alzheimer’s disease in patients over the age of 50.

STUDY DESIGN Systematic review of two randomized controlled trials published in 2006 and 2013 and one randomized controlled trial pooled analysis published in 2014.

DATA SOURCES Two randomized controlled trials and one pooled analysis were obtained using PubMed.

OUTCOMES MEASURED Efficacy of memantine as compared to control groups based on cognition, behavior, and adverse events. These were measured using Severe Impairment Battery (SIB), Neuropsychiatric Inventory (NPI), and Behavioral Pathology …

Does Herbal Medicine Have An Effect On The Cognitive Function Of Patients With Mild To Moderate Alzheimer’S Disease Over The Age Of 50?, Melissa Liebman

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE: The objective of this selective evidence based medicine review is to determine whether or not “herbal medicine has an effect on the cognitive function of patients with mild to moderate Alzheimer’s disease over the age of 50”.

STUDY DESIGN: Review of three double-blind, randomized control trials published between 2003 and 2015. All studies were published in English language in peer reviewed journals.

DATA SOURCES: Three randomized control trials were found via PubMed.

OUTCOMES MEASURED: The outcomes measured include changes in Alzheimer’s symptoms based upon a neurologist, improvement of Alzheimer’s symptoms based on ADAS-cog and CDR-SOB clinical rating scale, and …

Chlamydia Pneumoniae: An Etiologic Agent For Late-Onset Dementia, Brian J. Balin Phd, Christine Hammond, Christopher S. Little, Susan Hingley, Zein Al-Atrache, Denah Appelt, Judith A Whittum-Hudson, Alan P Hudson

PCOM Scholarly Papers

The disease known as late-onset Alzheimer's disease is a neurodegenerative condition recognized as the single most common form of senile dementia. The condition is sporadic and has been attributed to neuronal damage and loss, both of which have been linked to the accumulation of protein deposits in the brain. Significant progress has been made over the past two decades regarding our overall understanding of the apparently pathogenic entities that arise in the affected brain, both for early-onset disease, which constitutes approximately 5% of all cases, as well as late-onset disease, which constitutes the remainder of cases. Observable neuropathology includes: neurofibrillary …

Is 30 Ml Cerebrolysin A Safe And Effective Drug For Improving Global And Cognitive Function In Patients With Alzheimer's Disease Aged 50 Years And Older With No Significant Comorbidities?, Anthony Champion

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use of 30 mL Cerebrolysin is a safe and effective drug for improving global and cognitive function in patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities.

STUDY DESIGN: Systematic review of three randomized controlled trials published between 2001-2006, all English language.

DATA SOURCES: Three randomized controlled trials comparing the efficacy of cerebrolysin to placebo in the treatment of individuals ages 50 and over with AD related cognitive and global functioning decline. All articles found using PubMed.

OUTCOMES MEASURED …

Is Rivastigmine Effective In The Treatment Of Alzheimer’S Disease?, Beena Patel

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE: The objective of this selective EBM review is to determine whether or not rivastigmine is effective for the treatment of Alzheimer’s Disease.

STUDY DESIGN: Review of two trials in the English language published in 2007 and 2010, and an open-label, singlearm, multi-center study from 2008.

DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing rivastigmine to a visually-matched capsule (placebo) was found using PubMed and Cochrane databases.

OUTCOMES MEASURED: Overall global performance using the Alzheimer’s Disease Assessment Scale (ADAS-cog), ability to perform activities of daily living, cognitive function using the mini mental status exam (MMSE), and neuropsychiatric symptoms using BEHAVE-AD.

RESULTS: …

Does Beta Amyloid Immunization Reduce Amyloid Plaques And Preserve Cognitive Function In Patients With Alzheimer’S Disease?, Andrea Sasin

PCOM Physician Assistant Studies Student Scholarship

Objective: The objective of this systematic review is to examine the efficacy of beta amyloid immunization in reducing amyloid plaques and preserving cognitive function in patients with Alzheimer’s disease (AD).